GlobalData on MSN
Novocure’s stock rises 37% on FDA clearance of pancreatic cancer treatment device
Novocure’s Optune Pax delivers electric tumour treating fields (TTFields), targeting the electrical properties of cancer cells to thwart their survival and division.
The US Food & Drug Administration (FDA) has cleared Novocure’s Optune Pax device for locally advanced pancreatic cancer treatment, representing the first clearance by the agency in this indication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results